Technology

Sirius Genomics' expertise lies in our ability to correlate genes to physical attributes. Specifically, we look at Single Nucleotide Polymorphisms (SNPs) within genes of interest to determine the phenotypes that are associated with the individual SNPs. In studying these correlations, we look for SNPs that function as biomarkers and SNPs that act as Improved Response Polymorphisms (IRPs). IRPs are SNPs that are predictive of a positive response to a drug. We also identify Adverse Response Polymorphisms (ARPs), SNPs that are associated with an adverse reaction to a drug. These genetic correlations to clinical outcomes form the proprietary foundation for the diagnostic and pharmacogenetic tests that Sirius Genomics develop.

Our research and development process is tracked by three different stages: Discovery Phase I, Intellectual Property and Discovery Phase II. In Discovery Phase I, Sirius Genomics derives its initial SNP correlations (hypotheses) using our proprietary database. Once our derivation data is solidified, we file worldwide patent applications to protect our discoveries. In the final stage of our R&D, we validate our findings using external patient cohorts. This process advances Sirius Genomics towards commercialization of its products.